MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.athoracsur.2016.03.026

Медицинская библиотека · The Annals of thoracic surgery · 2016

Outcomes on Continuous Flow Left Ventricular Assist Devices: A Single Institutional 9-Year Experience.

Morgan Jeffrey A, Go Pauline H, Xuereb Linnea, Kaur Babbaljeet, Akrawe Silvy, Nemeh Hassan W, Borgi Jamil, Lanfear David E, Williams Celeste T, Paone Gaetano

Оценочное исследованиеСтатьяПеревод в очереди

Аннотация

BACKGROUND

Continuous-flow left ventricular assist devices (LVADs) have become the standard of care for patients with advanced heart failure. The goal of this study was to review our 9-year institutional experience.

METHODS

From March 2006 through May 2015, 231 patients underwent implantation of 240 CF LVADs, HeartMate II LVAD (Thoratec Corp., Pleasanton, CA; n = 205) or HVAD (HeartWare Inc., Framingham, MA; n = 35). Of these, 127 devices (52.9%) were implanted as bridge to transplantation (BTT) and 113 (47.1%) as destination therapy (DT).

RESULTS

Mean age was 51.2 ± 11.9 years for BTT patients and 58.2 ± 11.4 years for DT patients (p < 0.001). There was a higher incidence of preoperative diabetes, renal insufficiency, peripheral vascular disease, and previous cardiac operation in DT patients (p < 0.05). Survival was higher for BTT patients, with 1-, 6-, 12-, and 24-month survivals of 91.0%, 90.0%, 88.5%, and 72.1%, respectively, versus 85.3%, 81.1%, 75.6%, and 59.0%, respectively, for DT patients (p = 0.038). Gastrointestinal bleeding was the most common complication (29.6%), followed by right ventricular failure (22.5%) and stroke (15.0%), with a similar incidence for BTT and DT patients. Preoperative liver biopsy (hazard ratio [HR] 2.27, p = 0.036), mechanical support (HR 1.82, p = 0.025), aspartate transaminase (HR 1.07, p = 0.001), and alanine aminotransferase (HR 0.95, p = 0.024) were severe independent predictors of survival in multivariate analysis.

CONCLUSIONS

These data indicate excellent survival for BTT and DT patients on long-term LVAD support. However, for LVAD therapy to become a plausible alternative to heart transplantation, we need to further decrease the incidence of postoperative complications.

Для цитирования: Morgan Jeffrey A, Go Pauline H, Xuereb Linnea, Kaur Babbaljeet, Akrawe Silvy, Nemeh Hassan W, Borgi Jamil, Lanfear David E, Williams Celeste T, Paone Gaetano. Outcomes on Continuous Flow Left Ventricular Assist Devices: A Single Institutional 9-Year Experience.. The Annals of thoracic surgery. 2016. DOI: 10.1016/j.athoracsur.2016.03.026.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.